醫療事務(2030年) - 策略性演進

醫療事務正在經歷一場變革性演變，到 2030 年將成為製藥業的基石。

醫療事務部將與研發和商業團隊一起，從支援職能轉變為策略領導角色，並隨著人工智慧和遠距醫療等數位技術的整合而發展。此外，醫療事務部強調以患者為中心的策略並代表患者的聲音，以確保護理滿足患者的需求。

為了撰寫本報告，我們採訪了醫學事務顧問兼醫學科學聯絡 (MSL) 執行長 Samuel Dyer。我們與醫學科學聯絡 (MSL) 協會討論了以病人為中心的方法和 RWE 在醫療事務發展中的作用，並總結了他們的演講。

報告內容

• 到 2030 年，醫療事務的角色將如何演變？
• 人工智慧和遠距醫療等數位科技將如何影響醫療事務？
• 未來醫療事務將如何加強以病人為中心的護理
• RWE 在未來的醫療事務中將扮演什麼角色以及它將如何影響臨床決策？
• 醫療事務與其他部門的合作將如何改變？
• 監管環境預計會發生哪些變化以及醫療事務將如何適應？
• 未來醫療事務專業人員需要哪些新技能和能力？
• 未來將如何衡量和證明醫學事務活動的影響力？
• 未來十年醫療事務面臨的最大課題與機遇
• 醫療事務部將如何推動創新並適應快速變化的醫療保健環境

Medical affairs is poised for a transformative evolution by 2030, becoming a cornerstone of the pharmaceutical industry.

Transitioning from a support function to a strategic leadership role alongside R&D and commercial teams, medical affairs' evolution is driven by the integration of digital technologies like AI and telehealth. Furthermore, medical affairs will focus on patient-centric strategies, representing patient voices to ensure treatments meet their needs.

FirstWord spoke to Samuel Dyer, medical affairs consultant and CEO of the Medical Science Liaison (MSL) Society, about the role of patient-centric approaches and RWE in the evolution of medical affairs.

Key Questions Answered:

• How do you see the role of medical affairs evolving by 2030?
• What impact do you think digital technologies, such as AI and telehealth, will have on medical affairs?
• How will medical affairs enhance its focus on patient-centric care in the coming years?
• What role will RWE play in the future of medical affairs, and how will it influence clinical decision making?
• How do you foresee the collaboration between medical affairs and other departments changing?
• What changes do you anticipate in the regulatory landscape, and how will medical affairs adapt?
• What new skills and competencies will be essential for medical affairs professionals in the future?
• How do you think the impact of medical affairs activities will be measured and demonstrated in the future?
• What are the biggest challenges and opportunities you foresee for medical affairs over the next decade?
• How will medical affairs drive innovation and adapt to the rapidly changing healthcare environment?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.